Samsung Bioepis and Epis NexLab Partner with G2GBIO to Develop Long-acting Semaglutide and Novel Drug Delivery Assets
Tuesday, March 17, 2026
Samsung Bioepis and Epis NexLab have expanded their collaboration with G2GBIO beyond a standard licensing deal, signalling a broader strategic move into long-acting drug delivery and metabolic therapies.
The partnership focuses on developing therapies using G2GBIO’s microsphere-based sustained-release platform, which enables controlled drug release over extended periods. This approach is designed to reduce dosing frequency and improve patient adherence, particularly for chronic conditions such as diabetes and obesity.
The long-acting semaglutide asset is especially significant, as semaglutide is widely used in the treatment of type 2 diabetes and obesity. Developing a long-acting formulation could enhance convenience and potentially improve treatment outcomes in the growing GLP-1 therapy market.
In addition to development rights, the agreement strengthens the relationship between the companies through financial investment. Samsung Epis Holdings has committed to investing approximately KRW 20 billion in G2GBIO via convertible bonds, indicating long-term strategic intent rather than a short-term collaboration.
The deal also includes reciprocal development opportunities. While Samsung Bioepis gains licensing and negotiation rights for multiple assets, G2GBIO retains certain rights, including the ability to participate in future product development and supply, supporting its plans to expand manufacturing capabilities.
This collaboration aligns with Samsung Bioepis’ broader shift beyond biosimilars into novel drug development and advanced delivery platforms.
Source: samsungbioepis.com
